Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Withdrawn 2Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2CNS 2NET 1Head & Neck 1

Conditions

Neuroendocrine Tumors 3Pheochromocytoma 2Paraganglioma 2Pituitary Neoplasms 1Parathyroid Neoplasms 1Gastro-enteropancreatic neuroendocrine tumor 1Carcinoma, Medullary 1

Interventions

lutetium Lu 177 dotatate 2veliparib 1vandetanib 1Temozolomide 1Capecitabine 13-fluorobenzylguanidine 13-Iodobenzylguanidine 1177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Pheochromocytoma × lutetium Lu 177 dotatate × Clear all
NCT03923257 2021-06-08

Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents

University of Iowa

Phase 1/2 Withdrawn
CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT04106843 2020-09-07

Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers

M.D. Anderson Cancer Center

Phase 2 Withdrawn
CNSEndocrineHead & Neck

Paraganglioma, Parathyroid Neoplasms, Pheochromocytoma, Pituitary Neoplasms, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡